BOUDRY, Switzerland, Dec 6 (Bernama-BUSINESS WIRE) -- Celgene
Corporation (NASDAQ:CELG) today announced interim results from the
ABOUND clinical trial program evaluating the use of ABRAXANE®
(paclitaxel protein-bound particles for injectable suspension)
(albumin-bound) in patients with advanced non-small cell lung cancer
(NSCLC). Interim data being presented from the ABOUND trials during the
IASLC 17th World Conference on Lung Cancer (WCLC) reinforces the benefit
of ABRAXANE/carboplatin doublet therapy in first-line NSCLC.
http://mrem.bernama.com/viewsm.php?idm=28077
No comments:
Post a Comment